MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005)
Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dL and Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose
Maximum Waist Circumference Reduction of 3.9 Inches and Mean Reduction of 1.6 Inches Demonstrates Strong Signal of Glucagon Efficacy at Day 33 at 32 mg Dose
Additional Cohorts Being Added to Determine Maximum Tolerated Dose
Planned Phase 1 Part 3 to Include Wegovy® Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints
Market Data 
Markets 
AI
